Cardiac Bypass Surgery: Procedure, Benefits| My Medic Plus — Cost, Top Hospitals & Success Rates | MyMedicPlus

Cardiac bypass surgery — formally known as coronary artery bypass grafting (CABG) — is a major open-heart surgical procedure designed to restore adequate myocardial perfusion by routing blood flow around severely narrowed or blocked coronary arteries. Atherosclerotic plaques that accumulate within the coronary arteries progressively restrict blood supply to the heart muscle, precipitating angina pectoris, heart failure, and acute myocardial infarction. CABG creates new conduits that bypass these obstructions, re-establishing oxygen-rich blood flow to ischaemic myocardium.

The procedure is performed by a cardiothoracic surgeon on a patient placed under general anaesthesia. In conventional CABG, the chest is opened via a median sternotomy, and the patient is connected to a cardiopulmonary bypass (heart-lung) machine that temporarily assumes cardiac and pulmonary function, allowing the surgeon to operate on a still, bloodless heart. Bypass conduits are harvested from the patient's own vessels — most commonly the internal mammary artery (left internal thoracic artery, LITA) and saphenous vein from the leg, with the radial artery from the forearm used as an additional arterial conduit when total arterial revascularisation is planned.

Each graft is anastomosed proximally to the aorta and distally to the coronary artery beyond the blockage. A typical CABG involves two to five bypass grafts depending on the number of diseased vessels. The procedure takes three to six hours. After completion, the heart is restarted, the patient is weaned from bypass, and the sternum is closed with stainless steel wires. Modern CABG carries an operative mortality of less than 1 to 2% in elective cases at high-volume cardiac surgery centres, rising to 3 to 8% in urgent or complex cases with impaired left ventricular function.

CABG is the treatment of choice for severe multivessel coronary artery disease (CAD), particularly left main coronary artery disease (stenosis greater than 50%), triple-vessel disease with impaired left ventricular function (ejection fraction below 35%), and complex two-vessel disease involving the proximal left anterior descending (LAD) artery. The SYNTAX score, which quantifies angiographic complexity of CAD, guides the decision between CABG and percutaneous coronary intervention (PCI); high SYNTAX scores (above 32) consistently favour CABG in both survival and repeat revascularisation outcomes per the landmark SYNTAX trial.

Secondary indications include failed PCI with ongoing ischaemia (bail-out CABG), cardiogenic shock complicating acute myocardial infarction in surgically accessible anatomy, and combined valve and coronary disease requiring simultaneous valve repair or replacement with revascularisation. Diabetic patients with multivessel CAD derive particularly pronounced survival benefit from CABG over PCI, as demonstrated by the FREEDOM trial (NEJM, 2012), where CABG reduced death, myocardial infarction, and stroke by 47% at five years compared to drug-eluting stents.

The ideal candidate for CABG is a patient with angiographically confirmed significant coronary stenoses (typically greater than 70%) in multiple vessels or the left main coronary artery, symptomatic despite optimal medical therapy (antianginal medications, statins, antiplatelets), and with preserved or moderately impaired ventricular function. Patients must be able to tolerate the physiological stress of major surgery and general anaesthesia, require preoperative assessment of renal, hepatic, pulmonary, and neurological function. A multidisciplinary heart team — comprising interventional cardiologists, cardiac surgeons, and imaging specialists — reviews each case to determine the optimal revascularisation strategy.

Contraindications include prohibitive surgical risk due to severe left ventricular dysfunction (ejection fraction below 20%), severe chronic obstructive pulmonary disease, active systemic infection, uncorrectable coagulopathy, or patient refusal. Severely calcified or diffusely diseased small-calibre distal vessels with poor runoff may preclude technically satisfactory graft anastomoses. Elderly patients (above 80 years) with multiple comorbidities may be better served by PCI or transcatheter approaches, though age alone is not an absolute contraindication to CABG in otherwise fit individuals.

Conventional on-pump CABG uses cardiopulmonary bypass to achieve cardiac arrest, providing optimal surgical conditions. Off-pump CABG (OPCAB) is performed on the beating heart using stabiliser devices, avoiding aortic cannulation and the systemic inflammatory response of bypass; outcomes are equivalent in experienced hands, with potential benefit in high-risk patients with heavily calcified aortas. Minimally invasive direct CABG (MIDCAB) accesses the heart through a small left anterior thoracotomy without sternotomy, using the LITA to bypass the LAD artery; it is suitable for isolated single-vessel LAD disease.

Total arterial revascularisation strategies using bilateral internal mammary arteries (BIMA) and radial arteries reduce long-term graft failure compared to vein grafting, with 10-year patency rates of 90 to 95% for arterial grafts versus 50 to 60% for saphenous vein grafts. Robotic-assisted CABG (RA-CABG) enables LITA harvesting and anastomosis through small port incisions, further reducing surgical trauma in selected patients. Hybrid coronary revascularisation combines minimally invasive CABG for the LITA-LAD graft with PCI for non-LAD lesions, balancing the durability of arterial grafting with the reduced invasiveness of catheter-based techniques. The treating surgeon individualises the chosen technique based on patient anatomy, the extent and nature of the underlying condition, available equipment, and the balance of procedural benefit against risk — a decision made in consultation with the patient following a thorough informed consent discussion covering all available options.

CABG provides durable, complete myocardial revascularisation that significantly reduces angina, improves exercise capacity, and prolongs survival in appropriately selected patients. The ACC/AHA guidelines assign a Class I recommendation to CABG for left main disease, three-vessel disease with reduced ejection fraction, and diabetes with multivessel disease. Studies demonstrate 85 to 90% freedom from angina at five years post-CABG, with survival advantage over medical therapy persisting at 10 years. The LITA-to-LAD graft has a patency rate exceeding 90% at 15 years, making it one of the most durable vascular conduits in cardiovascular surgery.

Beyond symptom relief, successful CABG reduces the risk of future myocardial infarction, sudden cardiac death, and hospitalisation for acute coronary events. Patients with ischaemic cardiomyopathy and hibernating myocardium frequently experience meaningful improvement in ejection fraction following revascularisation, sometimes converting severe left ventricular dysfunction to moderate or mild impairment. Quality of life improves substantially, with most patients returning to full physical activity within three months of surgery.

Peri-operative risks of CABG include myocardial infarction (1 to 3%), stroke (1 to 3% for elective surgery, higher in those with carotid disease or heavily calcified aortas), acute kidney injury requiring temporary dialysis (2 to 5%), and pulmonary complications including pneumonia and atelectasis (5 to 10%). Atrial fibrillation is the most common post-CABG arrhythmia, occurring in 20 to 40% of patients, typically on postoperative days two to four, and is managed with amiodarone or beta-blockers. Sternal wound infection, including deep sternal wound infection or mediastinitis, occurs in 1 to 2% of cases and is a serious complication requiring surgical debridement.

Long-term complications include graft failure — saphenous vein grafts have a 10-year patency of approximately 50%, while internal mammary artery grafts maintain greater than 90% at 10 years. Recurrent angina due to disease progression in native arteries or graft stenosis may necessitate repeat revascularisation in 10 to 20% of patients at 10 years. Neurocognitive effects, formerly attributed to cardiopulmonary bypass, are now understood to reflect patient-specific risk factors rather than the bypass circuit alone, with most cognitive deficits resolving within three months postoperatively.

Hospital stay after CABG is typically five to seven days, with the first 24 to 48 hours spent in the cardiac intensive care unit for haemodynamic monitoring, ventilator weaning, and arrhythmia management. Sternal wound care, respiratory physiotherapy, and early mobilisation begin on the first postoperative day. Patients are discharged with aspirin (indefinitely) and a statin, along with beta-blockers, ACE inhibitors, and diuretics tailored to individual haemodynamic status. The sternum requires six to eight weeks for bony union; during this period, patients should avoid lifting objects greater than 5 kg and pushing/pulling activities that stress the sternum.

Cardiac rehabilitation — a structured exercise and education programme — commences four to six weeks post-discharge and is associated with a 25 to 30% reduction in cardiovascular mortality at five years per Cochrane meta-analysis. Driving is typically restricted for four to six weeks postoperatively. Follow-up cardiology reviews occur at six weeks, three months, six months, and annually, including echocardiography to assess ventricular function and stress testing if new symptoms emerge. Dietary modification, smoking cessation, and aggressive cardiovascular risk factor management (target LDL below 1.8 mmol/L) are critical to preserving graft longevity.

CABG is among the most expensive elective surgical procedures, reflecting the complexity of cardiac surgery, ICU care, and extended hospitalisation. In the United States, the all-inclusive cost of CABG ranges from USD 70,000 to USD 200,000, depending on the number of grafts, hospital tier, and complication rates. In the United Kingdom, private sector costs are approximately GBP 20,000 to GBP 40,000, while NHS waiting times for elective CABG can extend to six to twelve months.

Medical tourism for CABG offers compelling savings without compromising quality at JCI-accredited cardiac surgery centres. In India (Apollo, Fortis, Medanta), CABG costs USD 5,000 to USD 9,000 with internationally trained cardiac surgeons and outcomes equivalent to Western benchmarks. Thailand (Bumrungrad, Bangkok Hospital) charges USD 10,000 to USD 18,000, and Turkey (Medical Park, Acibadem) offers CABG at USD 8,000 to USD 14,000. Patients should verify surgeon volume (minimum 200 isolated CABG cases per year), ICU staffing ratios, and perioperative cardiac anaesthesia expertise before choosing an international centre.

Percutaneous coronary intervention (PCI) with drug-eluting stents is the primary alternative to CABG for single-vessel and selected two-vessel disease. PCI is less invasive, requires shorter recovery, and achieves equivalent outcomes in low-SYNTAX-score disease, but carries higher rates of repeat revascularisation in multivessel and complex lesions. The choice between CABG and PCI should be made by a multidisciplinary heart team following shared decision-making with the patient.

Optimal medical therapy (OMT) alone — comprising antiplatelet agents, high-intensity statins, ACE inhibitors, beta-blockers, and lifestyle intervention — is appropriate for patients with mild-to-moderate CAD without critical left main or proximal LAD involvement. The ISCHEMIA trial demonstrated that OMT achieves similar outcomes to revascularisation for stable ischaemic heart disease with preserved ventricular function. Transmyocardial laser revascularisation (TMR) and enhanced external counterpulsation (EECP) are additional non-surgical options for refractory angina in patients who are not candidates for conventional revascularisation.